RGLS250516C3000
- 0.20
- +0.10+100.00%
Regulus Therapeutics Newsroom
Is Regulus Therapeutics Inc. (RGLS) the Best Rising Penny Stock to Buy According to Analysts?
New Analyst Forecast: $RGLS Given 'Overweight' Rating
Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit
Regulus Therapeutics Leads The Charge Among 3 Promising Penny Stocks
Oppenheimer Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $7
Wells Fargo Upgrades Regulus Therapeutics(RGLS.US) to Buy Rating, Raises Target Price to $6
Sector Update: Health Care Stocks Advance Late Afternoon
Top Midday Gainers
Wells Fargo Upgrades Regulus Therapeutics to Overweight From Equalweight, $6 Price Target; Share Rise
Regulus Therapeutics Completes Phase 1b Farabursen Study in Polycystic Kidney Disease
Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease
$RGLS Stock Is up 20% Today. Here's What We See in Our Data.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Express News | Regulus Therapeutics Inc -on Track for Initiation of Phase 3 Single Pivotal Trial in Q3 2025
Express News | Regulus Therapeutics-Patients Receiving 300 Mg Farabursen Demonstrated Mean Halting of Height-Adjusted Total Kidney Volume Growth Over 4 Months
Express News | Regulus Therapeutics Inc -Positive Topline Data From Fourth Cohort of Patients
Express News | Regulus Therapeutics Announces Successful Completion of Its Phase 1B Multiple-Ascending Dose (Mad) Clinical Trial of Farabursen (Rgls8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (Adpkd)
Regulus Therapeutics Announces Successful Completion of Its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Canaccord Genuity Maintains Buy on Regulus Therapeutics, Maintains $28 Price Target
Is Regulus Therapeutics (NASDAQ:RGLS) In A Good Position To Invest In Growth?